The Swedish Knowledge-Foundation has granted SEK 12 million to a project concerning individual immunity profiles for diagnostics and medical development based on Attana's QCM technology.
The Swedish Knowledge-Foundation has granted SEK 12 million to the project "Advanced materials for individualized medicine and diagnostics". The project is coordinated by Prof. Ian Nicholls at Linnaeus University in collaboration with Attana AB, AroCell AB, Capitainer AB, Luma Metall AB and Region Kalmar.
The aim of the project is to provide precise information about the medical conditions of individuals and groups to optimize vaccination and medical treatment. It enables individuals, patients, care providers and decision makers, as well as researchers to optimize their decisions. The project includes the entire chain from sampling, via analysis to reporting. The project's participants gather expertise from the commercial and public sectors as well as researchers and developers.
The project consists of four sub-projects:
1. Biomarkers: Cancer biomarker detection – small cell lung cancer (Project manager: Ian Nicholls).
2. Viruses: Virus-related diseases: e.g. COVID-19 and hepatitis (Project manager: Per Nilsson).
3. Bacteria: Enhanced bacterial infection diagnosis – Lyme disease & E.coli related urinary tract infections (Project manager: Sofia Somajo).
4. Tissue samples: Biosensor-based histology – glaucoma & macular degeneration (Project manager: Camilla Mohlin).
Sub-project 1-3 builds directly on Attana's immunity profile concept and sampling with Capitainer's qDBS concept. Subproject 4 is based on Attana's tissue-based biosensors.
Shortly we will publish PMs regarding each specific sub-project and its importance for Attana.
Attana's CEO Teodor Aastrup comments:
"The project strengthens our capabilities in immunity profiles and ensures the necessary expertise and funding for the further development of immunity profiles. Thereby we can allocate the necessary resources to this project and at the same time focus other resources on our regular commercial activities."
For more information, please contact:
Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags: